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Abstract
Background: Dabigatran, an oral direct thrombin inhibitor, possesses several advantages over warfarin that can in principle
simplify the management of stroke prevention in atrial fibrillation (AF). Nonetheless it remains unclear whether these
advantages can translate to clinical practice and encourage long-term therapy. The objective was to describe long-term
dabigatran therapy for stroke prevention in AF and to identify risk factors for discontinuation of therapy.
Methods and Results:We studied 467 consecutive Chinese patients (72611 years, male: 53.8%) with a mean CHA2DS2-VASc
score of 3.6 prescribed dabigatran for stroke prevention in AF from March 2010 to September 2013. Over a mean follow-up
of 16 months, 101 patients (21.6%) permanently discontinued dabigatran. The mean time-to-discontinuation was 8 months.
The most common reason for discontinuation was dyspepsia (30.7%), followed by other adverse events (17.8%) such as
minor bleeding (8.9%), major gastrointestinal bleeding (7.9%), and intracranial hemorrhage (1%). Other reasons included
dosing frequency (5.9%), fear of side effects (4.0%), lack of laboratory monitoring (1.0%), and cost (1.0%). Multivariable
analysis revealed that low baseline estimated glomerular filtration rate (p= 0.02), absence of hypertension (p= 0.01), and
prior use of a proton-pump inhibitor (p= 0.02) and H2-receptor blocker (p= 0.01) were independent predictors of drug
discontinuation. In addition, there were altogether 9 ischemic strokes (1.5%/years), 3 intracranial hemorrhages (0.5%/year),
and 24 major gastrointestinal bleedings (4.1%/year).
Conclusion: Dabigatran discontinuation is very common amongst Chinese AF patients. This reveals a management gap in
the prevention of stroke in AF.
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Introduction
Atrial fibrillation (AF) is the most common sustained cardiac
arrhythmia encountered in clinical practice.[1,2] Patients with AF
have a 5-fold higher risk of ischemic stroke.[1] While the role of
long-term oral anticoagulation therapy in the form of vitamin K
antagonist for stroke prevention in AF has been established for
many years, such therapy is grossly underutilized amongst
Chinese: only 15% of Chinese AF patients eligible for long-term
anticoagulation therapy actually receive it.[3] This may be related
to a higher risk of intracranial hemorrhage amongst Chinese
prescribed a vitamin K antagonist,[4–6] a widely held belief of low
ischemic stroke risk amongst Chinese AF patients,[7],[8,9] and the
potential for herb-drug interaction due to the high prevalence of
herbal consumption in Chinese.[10]
Dabigatran, an oral direct thrombin inhibitor, was approved for
stroke prevention in patients with non-valvular AF by the US Food
and Drug Administration in 2010, and European Medicines
Agency in 2011. The drug has been commercially available in
Hong Kong since 2010. Dabigatran possesses several long-awaited
advantages over warfarin, such as a fixed dosing regimen that
requires no anticoagulation monitoring or dose adjustment, and
few drug-food and drug-drug interactions. This can, in principle,
simplify the management of stroke prevention in AF. Nonetheless
it remains unclear whether these advantages can enhance
continuation of therapy in clinical practice, and thus realize the
projected clinical benefits. In the RE-LY study, the 1-year and 2-
year discontinuation rate of dabigatran was ,15% and ,20%
higher than the corresponding rates for warfarin of only ,10%
and ,16%.[11] In this study, the objective was to describe
continued dabigatran therapy for stroke prevention in AF, and
identify the reasons and risk factors for discontinuation of therapy
in a cohort of Chinese AF patients.
Methods
Patients
Between March 2010 and September 2013, 500 patients at
Queen Mary Hospital prescribed Dabigatran were identified
through the computer-based clinical management system. Patients
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in whom dabigatran was prescribed for pulmonary embolism,
venous thrombosis or post-operative prophylaxis were excluded.
The final analysis included 467 Chinese patients with AF.
Study Design and Definitions
This was a single-center, registry-based, observational study.
The study protocol was approved by the Institutional Review
Board of Queen Mary Hospital. Informed consents were not
obtained from the patients given the registry nature of the study;
however, all patient records/information was anonymized and de-
identified prior to analysis. Data pertaining to baseline demo-
graphics, cardiovascular risk factors, gastrointestinal conditions
and medications were extracted from the electronic records of the
Clinical Management System Database. Hypertension was defined
as resting systolic and/or diastolic blood pressure $140/
90 mmHg on two occasions or prescription of anti-hypertensive
Table 1. Baseline characteristics.
All (n = 467) Dabigatran discontinuation P value
Yes (n =101) No (n=366)
Age, y 72611 71613 72610 0.86
Male 248 (53.1) 53 (52.5) 195 (53.3) 0.89
Mean CHADS2 2.0861.39 1.9561.46 2.1261.37 0.28
Mean CHA2DS2-Vasc 3.5861.86 3.4461.93 3.6261.84 0.37
Mean HAS-BLED 2.0261.07 1.9561.16 2.0461.05 0.68
Ever-smoker 89 (19.1) 21 (20.8) 68 (18.6) 0.62
Medical Conditions
CHF/LV dysfunction 111 (23.8) 33 (32.7) 78 (21.3) 0.02*
Hypertension 312 (66.8) 58 (57.4) 254 (69.4) 0.02*
Diabetes mellitus 124 (26.6) 25 (24.8) 99 (27.0) 0.64
Prior stroke/TIA 135 (28.9) 24 (23.8) 111 (30.3) 0.20
Intracranial hemorrhage 4 (0.9) 0 (0.0) 4 (1.1) 0.58
Myocardial infarction 26 (5.6) 8 (7.9) 18 (4.9) 0.24
Bleeding history 53 (11.3) 15 (14.9) 38 (10.4) 0.21
GERD 9 (1.9) 2 (2.0) 7 (1.9) 1.00
Esophagitis 15 (3.2) 3 (3.0) 12 (3.3) 1.00
Gastritis 50 (10.7) 11 (10.9) 39 (10.7) 0.95
Peptic ulcer disease 30 (6.4) 4 (4.0) 26 (7.1) 0.25
Drug induced dyspepsia 4 (0.9) 0 (0.0) 4 (1.1) 0.58
Functional dyspepsia 6 (1.3) 3 (3.0) 3 (0.8) 0.12
Prior H. pylori infection 28 (6.0) 8 (7.9) 20 (5.5) 0.36
Baseline Creatinine, mmol/L 93631 103643 90626 0.02*
Baseline eGFR, mL/min/1.73m2 66.6620.0 61.9619.9 67.9619.8 0.01*
Prior Medications
Warfarin 196 (42.0) 43 (42.6) 153 (41.8) 0.89
Aspirin 311 (66.6) 63 (62.4) 248 (67.8) 0.31
Thienopyridine 101 (21.6) 19 (18.8) 82 (22.4) 0.44
NSAIDs 152 (32.5) 32 (31.7) 120 (32.8) 0.83
Proton pump inhibitor 149 (31.9) 42 (41.6) 107 (29.2) 0.02*
Antacids 215 (46.0) 53 (52.5) 162 (44.3) 0.14
H2-receptor blocker 281 (60.2) 69 (68.3) 212 (57.9) 0.06
Concurrent Medications
Aspirin 70 (15.0) 19 (18.8) 51 (13.9) 0.22
Thienopyridine 16 (3.4) 2 (2.0) 14 (3.8) 0.54
NSAIDs 34 (7.3) 5 (5.0) 29 (7.9) 0.31
Proton pump inhibitor 196 (42.0) 46 (45.5) 150 (41.0) 0.41
H2-receptor blocker 194 (41.5) 41 (40.6) 153 (41.8) 0.83
Amiodarone 41 (8.8) 14 (13.9) 27 (7.4) 0.04*
*p,0.05. Abbreviations: CHF: congestive heart failure; eGFR, estimated glomerular filtration rate; GERD, gastroesophageal reflux disease; NSAIDs, non-steroidal anti-
inflammatory drugs; TIA: transient ischemic attack.
doi:10.1371/journal.pone.0101245.t001
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agents. Diabetes mellitus was defined as a serum fasting glucose $
7.0 mmol/l or prescription of anti-diabetic medication. Conges-
tive heart failure was defined according to the Framingham Heart
Study, and left ventricular (LV) systolic dysfunction was defined as
LV ejection fraction (EF) #40%. Obesity was defined as a body
mass index (BMI) $30 kg/m2. Glomerular filtration rate was
estimated (eGFR) using the following formula: eGFR =1756
(Scr/88.4)-1.1546 Age-0.20360.742 (if female) 61.212 (if African
American).[12] Ischemic stroke was defined as a neurological
deficit of sudden onset that persisted for.24 hours, corresponding
to a vascular territory in the absence of primary hemorrhage that
could not be explained by other causes (trauma, infection,
vasculitis). Stroke was confirmed by computerized axial tomogra-
phy or magnetic resonance imaging of the brain.[13,14] Intra-
cranial hemorrhage was diagnosed in the presence of new onset
neurological symptoms with radiological confirmation (computer-
ized axial tomography scan or magnetic resonance imaging).[15]
The CHADS2 score (Congestive heart failure, Hypertension,
Age$75 years, Diabetes, previous Stroke), more recently, the
CHA2DS2-VASc score (CHA2DS2-Vascular disease, Age 65-74
years, Sex category), and HAS-BLED score were calculated.
Study Outcomes
The primary endpoint was permanent discontinuation of
dabigatran during the follow-up period. Events such as temporary
discontinuation due to bleeding or need for surgery and death
within the follow-up period were not considered as discontinua-
tion. Other endpoints included the occurrence of clinical events
such as ischemic events, intracranial hemorrhage, and bleeding.
Major bleeding was defined as fatal bleeding, any bleed that
caused a reduction in haemoglobin level $2 g/dL, requirement
for transfusion of at least 2 units of whole blood or red cells, and/
or symptomatic bleeding in a critical area or organ. Minor
bleeding included any bleeding not considered as major bleeding.
Statistical Analysis
Continuous variables were expressed as mean 6 SD whereas
categorical variables were reported as frequencies and percentag-
es. Statistical comparisons of the baseline clinical characteristics
were performed using Chi-square test, Student’s t test, Mann-
Whitney U test or Fisher’s exact test as appropriate. Crude
incidence event rates were calculated as percentage per person-
years. The Cox proportional hazards regression model was used to
calculate the hazard ratios (HRs) of some predictive factors and
their 95% confidence intervals (CIs) for dabigatran discontinua-
tion. Variables with a p-value ,0.10 as determined in the
univariate analyses were added into the multivariable regression
model. A p-value ,0.05 was considered statistically significant.
Data analysis was performed using IBM SPSS Statistics 21 (SPSS,
Inc., Chicago, Illinois).
Results
Baseline Characteristics
Table 1 summarizes the baseline clinical characteristics of the
study cohort.
Figure 1. Kaplan Meier analysis of drug discontinuation rate.
doi:10.1371/journal.pone.0101245.g001
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A total of 467 patients were included in the final analysis. The
mean age was 72611 years with a male predominance (53.1%).
The mean CHADS2 score was 2.161.4, the mean CHA2DS2-
Vasc score was 3.661.9, and the mean HAS-BLED score was
2.061.1. Of the 467 patients, 312 patients had hypertension
(66.8%), 135 had prior stroke or transient ischemic attack (28.9%),
and 124 had diabetes mellitus (26.6%). The prevalence of pre-
existent upper gastrointestinal disease was varied: drug-induced
dyspepsia (0.9%), functional dyspepsia (1.3%), gastroesophageal
reflux disease (1.9%), esophagitis (3.2%), Helicobacter pylori
infection (6.0%), peptic ulcer disease (6.4), and gastritis (10.7%).
While the defaulted dose of dabigatran was 150 mg two times
daily, majority of patients (391 patients, 83.7%) in the present
cohort were prescribed 110 mg two times daily as in other Asian
countries. Only 47 patients (10.1%) were prescribed the standard
regime (150 mg two times daily). In addition 26 patients (5.6%)
were prescribed 75 mg two times daily mostly because of renal
impairment and elderly age.
Drug Discontinuation
Over a mean follow-up period of 16610 months (a total of
583.5 dabigatran-patient-years), dabigatran was discontinued in
101 of 467 patients (21.6%). The mean and median time-to-
discontinuation were 7.566.7 months and 5.5 months (inter-
quartile range: 2–12 months) respectively (Figure 1). Adverse
events and side effects accounted for most instances of discontin-
uation (62.4%)(Figure 1). Dyspepsia was the most common reason
for dabigatran discontinuation (30.7%), followed by bleeding
complications: major gastrointestinal bleeding in 8 patients (7.9%),
and intracranial hemorrhage in one (1.0%). Other side effects that
resulted in dabigatran discontinuation included skin rash, pruritus,
reflux symptoms, headache and generalized discomfort. In
addition, potential drug-drug interaction (3.0%) and worsening
of renal function (3.0%) were medical reasons for dabigatran
discontinuation. Patient concerns such as dosing frequency (5.9%),
fear of side effects (4.0%), monitoring concerns (1.0%) and
financial concerns (1.0%) accounted for 11.9% of dabigatran
discontinuation (Figure 2).
Table 1 summarizes the baseline clinical characteristics of
patients who discontinued therapy (21.6%) and those who
continued therapy (78.4%). There were no statistically significant
differences in age, gender, proportion of those prescribed warfarin,
CHADS2, CHA2DS2-VASc or HAS-BLED scores between those
who discontinued and those who continued dabigatran therapy.
Nonetheless those who discontinued treatment had a higher
proportion of congestive heart failure/LV systolic dysfunction
(32.7% vs. 21.3%, p=0.018), poorer baseline renal function
(eGFR: 62620 mL/min/1.73 m2 vs. 68620 mL/min/1.73 m2,
p=0.008; and serum creatinine: 103643 mmol/L vs.
90626 mmol/L, p=0.021), but a lower proportion of hyperten-
sion (57.4% vs. 69.4%, p=0.024). Interestingly, although there
was no significant difference in the incidence of previously
documented upper gastrointestinal conditions, those who discon-
tinued dabigatran were more likely to have been previously
prescribed a proton-pump inhibitor (41.6% vs. 29.2%, p=0.018).
Likewise, in patients who discontinued dabigatran a higher
Figure 2. Reasons of discontinuation of dabigatran.
doi:10.1371/journal.pone.0101245.g002
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proportion had previously taken amiodarone (13.9%, vs. 7.4%,
p=0.041). In multivariable analysis, only prior use of proton
pump inhibitors, and H2-receptor blockers, and baseline eGFR
were independent predictors of dabigatran discontinuation, while
prior stroke or transient ischemic attack and hypertension were
independently associated with continued of therapy (HR: 0.62,
95% CI: 0.39–0.98, p=0.042)(Table 2).
Clinical Events
During follow-up, there were 14 cerebral ischemic events (9
ischemic strokes or 5 transient ischemic attacks) with an annual
incidence of 2.4% (Table 3). The annual risk of ischemic stroke
and transient ischemic attack was 1.5% and 0.9% respectively. In
addition, there were altogether 98 bleeding complications with an
annual incidence of 16.8%. Amongst these, 31 constituted major
bleeding events (5.3%/year) including 24 major gastrointestinal
bleeds (4.1%/year), and 3 intracranial hemorrhages (0.5%/year).
In the cases of major gastrointestinal bleeding, 6 patients (25%)
were taking concomitant antiplatelet agents, 4 were on non-
steroidal anti-inflammatory agent, 2 were on amiodarone. In
addition, 12 of the 24 patients (50%) had a history of a pre-existent
upper gastrointestinal condition. Amongst the 3 patients with
intracranial hemorrhage, none was prescribed concomitant
antiplatelet therapy, but 1 was taking a non-steroidal anti-
inflammatory agent. There were 34 instances of minor gastroin-
testinal bleeding (5.8%/year), and 33 of minor bleeding at another
site such as the urinary tract, respiratory tract and subcutaneous
tissue (5.7%/year). There were 10 deaths (1.7%/year) during the
follow-up period: 3 were due to a cardiovascular cause (0.5%/
year). Furthermore, warfarin use prior to the initiation of
dabigatran was not associated with any clinical events.
Discussion
Dabigatran is the first oral anticoagulant approved by the Food
and Drug Administration for stroke prevention in non-valvular
AF, more than 50 years after warfarin was first approved. The
drug has overcome many of the major shortcomings of warfarin,
and more importantly has been proven to be comparable to
warfarin at a dose of 110 mg two times daily and superior to
warfarin at a dose of 150 mg two times daily in preventing stroke
in patients with non-valvular AF.[11] The translation of these
research findings to clinical benefits requires continuation of
Table 2. Associations between baseline factors and dabigatran discontinuation in Chinese AF patients.
Univariate Analysis Multivariable Analysis
HR (95% CI) p-value HR (95% CI) p-value
Age 0.99 (0.98–1.01) 0.35
Male 1.01 (0.68–1.49) 0.97
CHADS2 0.90 (0.78–1.04) 0.16
CHA2DS2-Vasc 0.94 (0.84–1.04) 0.22
HAS-BLED 0.92 (0.77–1.11) 0.40
Ever-smoker 1.09 (0.67–1.76) 0.72
Medical conditions
CHF/LV dysfunction 1.58 (1.04–2.40) 0.03* 1.37 (0.87–2.14) 0.17
Hypertension 0.62 (0.42–0.93) 0.02* 0.54 (0.35–0.83) 0.01*
Diabetes mellitus 0.89 (0.57–1.40) 0.62
Prior stroke/TIA 0.65 (0.41–1.04) 0.07 0.62 (0.39–0.98) 0.04*
Bleeding history 1.43 (0.83–2.48) 0.20
Gastritis 1.06 (0.57–1.99) 0.85
Baseline eGFR 0.99 (0.98–0.99) 0.02* 0.99 (0.98–0.99) 0.02*
Prior Medications
Warfarin 0.92 (0.62–1.36) 0.67
Aspirin 0.86 (0.57–1.28) 0.46
Thienopyridine 0.84 (0.51–1.39) 0.51
NSAIDs 0.98 (0.65–1.50) 0.94
Proton pump inhibitor 1.65 (1.11–2.46) 0.01* 1.64 (1.09–2.46) 0.02*
Antacid 1.31 (0.89–1.93) 0.18
H2-receptor blocker 1.55 (1.02–2.36) 0.04* 1.80 (1.16–2.82) 0.01*
Concurrent Medications
Aspirin 1.37 (0.83–2.26) 0.22
Proton pump inhibitor 1.10 (0.74–1.62) 0.65
H2-receptor blocker 0.89 (0.60–1.33) 0.57
Amiodarone 1.73 (0.99–3.05) 0.06 1.41 (0.79–2.55) 0.25
*p,0.05. Abbreviations: CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; LV, left ventricular; NSAIDs, non-steroidal anti-inflammatory drugs; TIA,
transient ischemic attack.
doi:10.1371/journal.pone.0101245.t002
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therapy. In the RE-LY study, the 2-year discontinuation rate of
dabigatran was .20%, much higher than for warfarin (16.6%). In
the present study, 21.6% of Chinese AF patients, more than 1 in 5
patients, prescribed dabigatran for stroke prevention discontinued
the drug over a mean follow-up of 16 months, a much higher rate
than that of the RE-LY study.[11] Nonetheless, the finding was
similar to real-world studies in Japan and Hong Kong which
reported discontinuation rates of 21.7% in 300 patients after a
median follow-up of 263 days and 25.4% in 122 patients after a
median follow-up of 310 days respectively.[16,17]
In our cohort, a vast majority of dabigatran discontinuation was
related to adverse events and/or side effects. Amongst these,
dyspepsia was the single most common reason, accounting for up
to 30% of instances (6.6% of patients, compared with 2% in the
RE-LY study).[11] Similarly, Miyamoto and colleagues observed
that discontinuation of dabigatran was mainly due to dyspepsia,
followed by deteriorating renal function, then minor bleeding.[16]
On the other hand, a multi-center study reported that high cost
accounted for half of the discontinuation whereas gastrointestinal
side effects such as dyspepsia and flatulence came next.[18] Of
note, dabigatran-induced dyspepsia was much more common in
the present cohort than in the RE-LY study (16.5% vs. 11.8% in
patients prescribed dabigatran 110 mg two times daily, and 11.3%
in those prescribed 150 mg two times daily).[11] In the Long-term
Multicenter Extension of Dabigatran Treatment in Patients with
Atrial Fibrillation (RELY-ABLE) study, which included almost
50% of patients originally randomized to dabigatran in the RE-LY
trial and who continued to receive the same blinded dabigatran
dose,[19] 21.5% of those prescribed 110 mg two times daily and
20.7% of those prescribed 150 mg two times daily reported
dyspepsia.[20]
Interestingly, while previously diagnosed upper gastrointestinal
conditions did not predict dabigatran discontinuation, prior use of
proton pump inhibitors and H2-receptor blockers did. This
suggests that some patients might have had pre-existent upper
gastrointestinal pathology that required treatment with a proton
pump inhibitor and H2-receptor blocker, and that was subse-
quently exacerbated by dabigatran. Nonetheless it has been
recently reported that simple measures such as taking dabigatran
with a meal, and use of a proton pump inhibitor, H2-receptor
blockers and/or non-prescription antacids can significantly
alleviate symptoms of dyspepsia.[20] In contrast, history of
hypertension and stroke was associated with lower discontinuation
risk. This may be explained by physicians’ perception of higher
stroke risk among this group of patients. Other adverse clinical
events, particularly bleeding complications, also contributed to
dabigatran discontinuation: the risk of bleeding in the present
cohort appeared to be higher than in the RE-LY trial: 16.8% per
year for major and minor bleeding compared with 14.6%/year in
dabigatran 110 mg two times daily, and 16.4%/year in 150 mg
two times daily. More importantly, the rate of intracranial
hemorrhage was 0.5%/year in the present cohort, substantially
higher than in the RE-LY trial (0.2% to 0.3%/year).[11] In the
recently published sub-study of RE-LY that included an Asian-
only population,[21] the annual risk of intracranial hemorrhage
was only 0.23%/year in patients on dabigatran 110 mg two times
daily and 0.45%/year in patients on dabigatran 150 mg twice
daily. Even more alarmingly, the rate of major gastrointestinal
bleeding was 4.11%/year in our cohort, substantially higher than
that of both the Asian (0.96%/year to 1.15%/year) and non-Asian
population (1.14%/year to 1.69%/year) in the RE-LY study.[21]
While some studies in the real world setting documented very few
bleeding events, ranging from 3.3% to 5.2%,[16,18,22] Michel
Table 3. Clinical events.
Annual event rate (%)
Ischemic events
Ischemic stroke/TIA, n (%) 14 (3.0) 2.4
Ischemic stroke, n (%) 9 (1.9) 1.5
TIA, n (%) 5 (1.1) 0.9
Myocardial Infarction, n (%) 3 (0.6) 0.5
Unstable angina, n (%) 1 (0.2) 0.2
Bleeding events
Any bleeding, n (%) 98 (21.0) 16.8
Major bleeding, n (%) 31 (6.6) 5.3
Intracranial, n (%) 3 (0.6) 0.5
Gastrointestinal, n (%) 24 (5.1) 4.1
Other, n (%) 4 (0.9) 0.7
Minor bleeding, n (%)
Gastrointestinal, n (%) 34 (7.3) 5.8
Other, n (%) 33 (7.1) 5.7
Gastrointestinal symptoms
Dyspepsia 77 (16.5) 13.2
Reflux 32 (6.9) 5.5
Death, n (%)
Cardiovascular, n (%) 3 (0.6) 0.5
All-cause, n (%) 10 (2.1) 1.7
doi:10.1371/journal.pone.0101245.t003
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and colleagues revealed that 29% of patients receiving dabigatran
had experienced bleeding events, predominantly minor ones.[23]
In particular, Ho and colleagues reported the total bleeding and
intracranial hemorrhagic risks of 22.95% and 1.64%, respectively,
which were even higher than that in our cohort.[17] This high
incidence of bleeding complications may be related to a high
prevalence of pre-existent upper gastrointestinal disorders and the
concomitant use of anti-platelet agents and/or non-steroidal anti-
inflammatory drug.
The results of our study have several important clinical
implications.
First, Chinese AF patients prescribed dabigatran had a high
drug discontinuation rate due to upper gastrointestinal side effects
or bleeding complications. This may be related to the higher
prevalence of pre-existent, undiagnosed upper gastrointestinal
disorders that were then subsequently revealed or exacerbated by
dabigatran. Thus, screening for upper gastrointestinal symptoms
prior to prescription of dabigatran may allow early identification
of upper gastrointestinal pathology, and thereby prevent bleeding
complications and improve treatment compliance. Second, as
dyspepsia and bleeding complications can be managed by proper
adjustment of medication and some simple measures, additional
support and counseling for patients on dabigatran therapy by
healthcare professionals may likewise improve compliance with
therapy.
Limitations
This observational study had some limitations. First, our study
was limited by the small sample due to a single-hospital registry,
although to our knowledge, this is the largest published Chinese
AF cohort prescribed Dabigatran.
Second, the decision to discontinue dabigatran was made by the
individual patient and their attending physician. Third, this was a
hospital-based study using single-hospital registry data and did not
include patients with a milder form of ischemic stroke, and/or
bleeding complications who did not require hospitalization.
Conclusion
Amongst Chinese patients prescribed dabigatran for stroke
prevention in AF, the discontinuation rate is substantial, mainly
due to adverse events and side effects. This study provides data on
the main reasons for dabigatran discontinuation in Chinese AF
patients. This may allow implementation of measures such as
patient education to improve drug compliance and thus ensure
continuation of therapy.
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